Boon, Gudula J. A. M.
Ende-Verhaar, Yvonne M.
Beenen, Ludo F. M.
Coolen, Johan
Delcroix, Marion
Golebiowski, Marek
Huisman, Menno V.
Mairuhu, Albert T. A.
Meijboom, Lilian J.
Middeldorp, Saskia
Pruszczyk, Piotr
van Rooden, Cornelis J.
Vonk Noordegraaf, Anton
Kroft, Lucia J. M.
Klok, Frederikus A.
Funding for this research was provided by:
Hartstichting (2017T064)
Merck Sharp and Dohme
Article History
Received: 19 May 2021
Revised: 5 September 2021
Accepted: 27 September 2021
First Online: 2 December 2021
Declarations
:
: The scientific guarantor of this publication is F.A. Klok.
: GJAMB was supported by the Dutch Heart Foundation (2017T064).YEV has no disclosures.LFMB has no disclosures.JC has no disclosures.MD has no disclosures.MG has no disclosures.MVH reports grants from ZonMW Dutch Healthcare Fund, grants and personal fees from Pfizer-BMS, grants and personal fees from Bayer Health Care, grants and personal fees from Daiichi-Sankyo and grants from Leo Pharma, outside the submitted work.ATAM has no disclosures.LJM has no disclosures.SM reports grants and personal fees from Daiichi Sankyo, grants and personal fees from Bayer, personal fees from BMS-Pfizer, personal fees from Boehringer-Ingelheim, personal fees from Portola and personal fees from Abbvie, outside the submitted work.PP has no disclosures.CJR has no disclosures.AVN is supported by the Netherlands CardioVascular Research Initiative (CVON-2012–08 PHAEDRA, CVON-2017–10 DOLPHIN-GENESIS) and the Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610). In addition, his institute received speaker’s money from Johnson & Johnson, MSD, Actelion, Bayer and Ferrer in the past 3 years. Finally, he served as a member of the scientific advisory board of Acceleron, MSD and Johnson & Johnson.LJMK has no disclosures.FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart Foundation (2017T064) and the Dutch Thrombosis association, all outside the submitted work.
: No complex statistical methods were necessary for this paper.
: All patients provided written informed consent before the start of any study procedure.
: The study protocol was approved by all institutional review boards of the participating hospitals.
: The current study is a predefined post hoc analysis based on results of the InShape II study, which was a prospective, multicentre management study assessing the accuracy of a non-invasive follow-up strategy for early identification of CTEPH in consecutive patients treated for acute PE. Of all 424 InShape II study patients, available CTPA scans at the time of index PE diagnosis were collected post hoc at each of the six study sites and were re-evaluated.